EMA approves Pfizer / BioNTech vaccine for children aged 5 to 11 – Healthcare – World – NOVA News

news/view/2021/11/25/347872/%D0%B5%D0%BC%D0%B0-%D0%BE%D0%B4%D0%BE%D0%B1%D1%80%D0%B8-%D0%B2%D0%B0%D0%BA%D1%81%D0%B8%D0%BD%D0%B0%D1%82%D0%B0-%D0%BD%D0%B0-pfizerbiontech-%D0%B7%D0%B0-%D0%B4%D0%B5%D1%86%D0%B0-%D0%BE%D1%82-5-%D0%B4%D0%BE-11-%D0%B3/">

The dosage will be lower than in the age group over 12 years.

The European Medicines Agency has recommended that the vaccine be approved by Pfizer / BioNTech for children aged 5 to 11 years. The dosage will be lower than in the age group over 12, the agency said.

The study showed that the immune response to the vaccine at a lower dose in this age group was the same as the higher dose in young people between 16 and 25 years of age.

‼️ EMA recommends approval of BioNTech/Pfizer’s #COVID19vaccine, Comirnaty, for children aged 5 to 11.

In this population, the dose of #Comirnaty will be lower than that used in people aged 12 and above.

Read the full press release: https://t.co/uqqBAklVvl pic.twitter.com/NZQhli4SDl

— EU Medicines Agency (@EMA_News) November 25, 2021

The decision follows a similar one taken by the United States Centers for Disease Control and Prevention (CDC) earlier in November and comes just over a month after the application was submitted by Pfizer / BioNTech.

–